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ABSTRACT
In Africa, epidemiological data on the effect of the HIV epidemic on the occurrence of lymphomas are 
scanty. The 1990s witnessed the alarming rates of HIV/AIDS in Nigeria. The prevalence of HIV/AIDS in   
Nigeria increased from 1.8% in 1991 to 4.4% in 2005. The aim of this study was to determine whether 
there have been any changes in the frequency and pattern of lymphomas in view of the HIV/AIDS epi-
demic in the country. This is a retrospective study of all lymphoma cases diagnosed during 1991-2005. The 
prevalence of lymphomas declined from 1.4% to 0.7% of surgical biopsies during 1991-2005. There was a 
decline in the proportion of high-grade non-Hodgkin lymphoma and Burkitt’s lymphoma from 79.1% and 
45.8% respectively to 21.1% and 13.6% respectively. There is a suggestion that the HIV/AIDS epidemic in 
the country may not have influenced the pattern of occurrence of both major histomorphological types 
of lymphoma in Ibadan. 
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INTRODUCTION
Lymphomas are a heterogeneous group of neo-
plasms of the lymphoid tissues traditionally cate- 
gorized as either Hodgkin’s lymphoma (HL) or 
non-Hodgkin’s lymphoma (NHL), each displaying 
distinct behavioural, prognostic and epidemiologi-
cal characteristics, with varying responses to treat-
ment. Approximately 287,000 new cases of NHL 
are reported in the world each year (1). This disease 
affects more males than females, and the incidence 
increases with age. In most African populations, 
NHL is relatively rare but the relative frequency is 
above the world average in North and sub-Saharan 
Africa because of the high incidence of Burkitt’s 
lymphoma (BL) in children in the tropical zone of 
Africa (2).
According to the 1976 report of the International 
Agency for Research on Cancer, Ibadan registered 
one of the highest incidences of lymphomas world- 
wide (3). The prevalence of BL, although still the 
commonest childhood malignancy in Ibadan, ac-
counting for 19.4% of all childhood malignancies 
in the 1990s, declined from 50% in the 1960s to 
37% in the 1970s and 1980s (4). This decline has 
been ascribed to improved living conditions, great-
er control of malaria, and probably decreasing in-
fection due to Epstein Barr Virus (EBV) (4,5). 
One of the most striking tumour associations in HIV-
related disease is the development of high-grade 
B-cell lymphomas. The high increases reported in 
the incidence of NHL in many parts of the world, 
particularly in developed countries, have been at-
tributed to the HIV pandemic (6,7). NHLs consti-
tute an AIDS defining disease in 2-3% of patients 
(8).  
In Africa, scanty epidemiological data are available 
on the effect of the HIV epidemic on the frequency 
of lymphomas and malignancies in general (9-11). 
The 1990s witnessed the alarming rates of HIV/
AIDS in Nigeria. The prevalence of HIV/AIDS in Ni-
geria increased from 1.8% in 1991 to 5.8% in 2001 
before eventually falling to 4.4% in 2005, with hot 
spot areas having rates as high as 21% (12). The ef-
fect of the HIV/AIDS epidemic on the pattern of 
lymphomas in Nigeria is yet to be defined. There 
has also not been any other comprehensive review 
of lymphomas in Ibadan since the last report in 
1991 (13). We, therefore, decided to review all cases 
of lymphomas diagnosed during 1991-2005. The Oluwasola AO et al. Declining incidence of lymphomas in Nigeria
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aim was to find out if any changes have been oc-
curred in the frequency and pattern of lymphomas 
since the last review, which is a period particularly 
characterized by a rising HIV/AIDS epidemic in the 
country.    
MATERIALS AND METHODS
This is a retrospective study of all cases with histo-
logical or cytological diagnosis of lymphomas reg-
istered in the Department of Pathology, University 
College Hospital (UCH), Ibadan, Nigeria, over a 15-
year period from January 1991 to December 2005.
The records of patients diagnosed to have lym-
phomas over the study period were obtained from 
the archival surgical and cytology registers of the 
department and from the Ibadan Cancer Registry, 
with a coverage population of about two million.
The NHL cases were categorized using the Work-
ing Formulation classification scheme while the 
HL cases were classified according to the Rye clas-
sification. The histological slides of cases not classi-
fied according to the Working Formulation in the 
original histology report were reviewed and reclas-
sified. Where the original histological sections were 
inadequate or unavailable, the paraffin blocks were 
retrieved from the archives of the Department of 
Pathology, UCH, Ibadan, and fresh haematoxylin-
eosin-stained sections were prepared and re-exam-
ined. Immunohistochemical examination was 
not performed on these cases as this service was not 
available in the institution during the study period. 
The HIV status of the patients was also not available 
since this test was not being routinely performed 
during the study period.  
Analysis of data
Data obtained were analyzed using the SPSS soft-
ware (version 11). Student’s t-test and Spearman’s 
correlation test were applied where appropriate, 
with level of significance set at p≤0.05.
Ethical aspects
This study was performed in compliance with the 
guidelines of the Helsinki Declaration on biomedi-
cal research on human subjects. It was a retrospec-
tive study, and confidentiality of the identity of 
the patients and personal health information was 
maintained.
RESULTS
Six hundred and thirty-eight cases of lymphomas 
were recruited, comprising 421 (66%) histologi-
cally- and 217 (34%) cytologically-diagnosed cases. 
These accounted for 0.9% of 47,177 surgical biop-
sies and 1.2% of 17,868 cytology specimens proc-
essed in the Department of Pathology during the 
study period.
There were 558 (87.5%) cases of NHL and 80 (12.5%) 
cases of HL. There was a progressive decline in the 
annual frequency of lymphoma from 58 cases in 
1991 to 24 cases in 2005 (Fig. 1), which represents 
a decrease from 1.4% to 0.7% of all surgical biopsies 
received during the same years in the Department 
of Pathology. The decrease was significant (χ2=17.4, 
p<0.0003). The decline was independently dem-
onstrated in both NHL and HL, and the decline in 
these individual subtypes was significant (χ2=12.11, 
p=0.005 and χ2=6.01, p=0.014 respectively). It was 
also  observed  that  the  relative  ratio  frequency 
of malignant lymphoma among other registered 
cancers fell from about 4.1% in 1991 to about 1.6% 
in 2005. 
Overall, there were 387 (60.7%) male patients 
and 251 (39.3%) female patients, representing a 
male:female ratio of 1.5:1. The age of patients with 
lymphoma ranged from one year to 85 years, with 
a mean age of 29.8 years. The second decade of life 
experienced the peak occurrence of lymphomas. 
The nodal sites were slightly more often involved 
(53.6%) than the extranodal sites (46.4%). Most 
(98.7%) extranodal lymphomas were NHL, and the 
majority (52.1%) of the cases occurred in children 
aged less than 17 years. 
Non-Hodgkin’s lymphoma
There were 336 (60.2%) male patients and 222 
(39.8%) female patients with NHL, with a male: 
female ratio of 1.5:1. Their mean age was 29.6 
years, and their ages ranged from one year to 85 
years. Forty-eight percent of the cases occurred in 
the first two decades of life.
Two hundred and thirty-five (53.5%) cases were 
extranodal while 204 (46.5%) were nodal. The to-
pography of 109 (21.3%) cases was not available. 
The commonest extranodal sites included the jaw 
(23.5%), nasopharynx and nasal cavity (7.4%), 
breast (5.2%), ovary (5.2%), and the gastrointesti-
nal tract (4.9%). The commonest nodal sites of 
involvement were the cervical (38.5%), axillary 
(17.8%), and inguinal (9.4%) regions. 
The commonest histological types of NHL were 
small non-cleaved cell (BL) (29.9%), diffuse large 
cell (15.5%), lymphoblastic (12.4%), and small lym-
phocytic lymphomas (9.6%) (Table 1). The jaw was 
the commonest site of occurrence of BL (37.1%), 
followed by the abdomen (16.8%), ovary (7.9%), 
and the breast (6.3%). The average age of occur-Oluwasola AO et al. Declining incidence of lymphomas in Nigeria
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Fig. 1. Relative ratio frequency and time trends for lymphomas
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rence of BL was lower in the jaw and abdomen (8.7 
and 9.8 years respectively) compared to the ovaries 
and breast (20.3 and 15.9 years respectively).
Of 508 cases which had grading from histology and 
cytology, 298 (58.7%) were high-grade lymphoma, 
and 145 (28.5%) were of intermediate grade while 
Table 1.   Age range, male:female ratio, relative frequency, and anatomic localization of lymphomas
Histological type
Age range
(years)
Male: 
female 
ratio
Frequency
Anatomical 
localization
nodal/extranodal No. %
Hodgkin’s lymphoma
   Nodular sclerosis 11-74 1.4:1 32 5.0 31/0
   Lymphocyte predominant 8-71 2:1 3 0.5 3/0
   Mixed cellularity 5-56 2.4:1 17 2.7 15/1
   Lymphocyte depleted 13-65 2:1 9 1.4 6/2
   Others* 12-71 1.7:1 19 3.0 16/0
Total 80 12.5 71/3
Non-Hodgkin’s lymphoma
   Small lymphocytic 11-81 1.4:1 61 9.6 36/21
   Follicular predominantly small cell - - 1 0.2 1/0
   Follicular mixed small and large cell 28-46 1:2 3 0.5 1/1
   Follicular predominantly large cell 24-46 2:1 3 0.5 3/0
   Diffuse small cleaved cell 11-67 1:1.3 9 1.4 4/3
   Diffuse mixed small and large cell 8-78 2.4:1 34 5.3 16/13
   Diffuse large cell 6-81 1.4:1 99 15.5 39/44
   Large cell immunoblastic 6-85 2.1:1 28 4.4 21/3
   Lymphoblastic 5-78 1.5:1 79 12.4 32/36
   Small non-cleaved cell 1-39 1.3:1 191 29.9 17/117
   Others* 4-80 2.5:1 50 7.8 34/7
Total 558 87.5 204/235
*Cases without histological subtypesOluwasola AO et al. Declining incidence of lymphomas in Nigeria
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Fig. 2. Trend in relative frequency of grades of non-Hodgkin lymphoma 
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65 (12.8%) were low-grade lymphomas (Fig. 2). 
There was a significant decline in the comparative 
proportion of high-grade NHL compared to inter-
mediate- and low-grade NHL  from about 79.1% in 
1991 to about 21.1% in 2005 (χ2=19.65, p<0.0001). 
A similar decline was observed in the relative ratio 
frequency of BL from an average of 45.8% in 1991 
to 15.8% in 2005. The difference was also signifi-
cant (χ2=5.25, p<0.03).  
All the histological subtypes of NHL with sample-
sizes of over 30 showed a male preponderance. The 
age of the patients diagnosed to have small non-
cleaved cell lymphoma (BL) ranged from one year 
to 39 years (mean 10.6 years), and the peak age 
of occurrence was in the first decade of life. Most 
(92%) patients were aged 1-14 years. 
Hodgkin’s lymphoma
HL was diagnosed in 51 (63.8%) male patients and 
in 29 (36.3%) female patients, giving a male:female 
ratio of about 1.8:1. The age range of occurrence 
was 5-74 years, with the mean age of 31.1 years. 
Sixty-six percent of the cases had HL before the age 
of 40 years while the modal age-group of occur-
rence was in the third decade of life. Most (88.8%) 
were nodal while 11.3% occurred at the extranodal 
sites, such as the intestine, liver, and spleen. The 
commonest nodal sites of involvement were the 
cervical, supraclavicular and axillary regions, in the 
descending order of frequency.
The commonest histological subtypes encountered 
were the nodular sclerosis (40%), followed by the 
mixed cellularity (21.3%) subtypes (Table 1). The 
lymphocyte-depleted subtype was most frequently 
diagnosed at the extranodal sites. All the histologi-
cal subtypes showed a male preponderance.
The mean age and age range of the various histo-
logical subtypes of HL are shown in Table 2. The 
nodular sclerosis subtype was diagnosed in patients 
aged 11-74 years, with a mean age at diagnosis of 
27 years. The age range of the lymphocyte-depleted 
subtype, however, was 13-65 years, with an average 
age of 43.1 years.
DISCUSSION
It is estimated that approximately 100,000 new cas-
es of cancer occurred yearly in Nigeria in the 1990s 
and that at the turn of the century, about 500,000 
new cases will occur annually (14). Lymphomas 
were the commonest tumours observed in Ibadan, 
Nigeria, during 1960-1980 (15), and Ibadan Cancer 
Registry data from a study in 2000 revealed that the 
comparative frequency of lymphoma in Ibadan dec- 
lined in the recent decades (16). A similar levelling 
off of previous rates of increase and decrease in in-
cidence rates of NHL has been recently reported in 
some Nordic countries and in the USA, albeit for 
reasons different from ours (17,18).
Earlier reports of decline in the incidence of BL 
have been ascribed to improved living conditions Oluwasola AO et al. Declining incidence of lymphomas in Nigeria
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Table 2. Age variables and male to female ratios of lymphoma patients
Histological type
Age range 
(years)
Mean age (years) (95% 
confidence intervals)
Male: 
female ratio
Hodgkin’s lymphoma
   Nodular sclerosis 11-74 27 (21.5-32.5) 1.4:1
   Lymphocyte predominant 8-71 35 (-1.2-71.9) 2:1
   Mixed cellularity 5-56 27 (19.5-35.0) 2.4:1
   Lymphocyte depleted 13-65 43 (32.0-54.3) 2:1
   Others* 12-71 34 (25.8-44.1) 1.7:1
Non-Hodgkin’s lymphoma
   Small lymphocytic 11-81 56 (51.6-60.2) 1.4:1
   Follicular predominantly small cell - - -
   Follicular mixed small and large cell 28-46 34 (22.2-45.8) 1:2
   Follicular predominantly large cell 24-46 32 (18.8-45.8) 2:1
   Diffuse small cleaved cell 11-67 41 (28.2-54.0) 1:1.3
   Diffuse mixed small and large cell 8-78 36 (29.5-43.0) 2.4:1
   Diffuse large cell 6-81 41 (37.7-45.2) 1.4:1
   Large cell immunoblastic 6-85 50 (41.7-57.9) 2.1:1
   Lymphoblastic 5-78 22 (18.1-26.8) 1.5:1
   Small non-cleaved cell 1-39 10 (9.8-11.3) 1.3:1
   Others* 4-80 45 (38.6-50.4) 2.5:1
*Cases without histological subtype
and greater control of malaria probably decreasing 
infection due to EBV, reduced referral load in the 
University College Hospital, Ibadan, and improved 
cancer registration procedures (4,5). While these 
various factors may still have a role in the current 
trend in the occurrences of lymphomas, the extent 
of their specific contributions needs to be explored 
in future studies. To determine whether the trends 
are real, there is a need to keep in mind various arte-
factual factors that could influence the reported in-
cidence without changing the true rate. These fac-
tors include completeness of registration, changes 
in disease classification, and advances in diagnostic 
technology (6). There have also not been any sig-
nificant decrease in staff strength or infrastructure 
of this registry that could have affected the data-
collection process. Similarly, changes in the inter-
national coding of disease in recent decades can-
not account for significant losses of lymphoma 
cases. A more likely source of an artefactual effect 
might have resulted from advances in diagnostic 
technology; this, however, would have resulted in 
the detection of more cases over time, which is not 
our present experience. Nevertheless, this centre 
has only acquired a few additional diagnostic tech-
nologies in recent decades, mainly for radiological 
diagnosis. 
HIV infection has been associated with a 60-fold 
increased risk of developing NHL in Western coun-
tries (19), and approximately 5-10% of HIV-infect-
ed persons will develop a lymphoma (20). The risk 
of HL is also increased in patients with HIV infec-
tion. In Africa however, the rate of association of 
NHL with HIV is 2.3-12.3% (21). The prevalence 
of HIV in Nigeria has consistently increased from 
1.8% in 1991 to 5.8% in 2001 before a decline to 
5% in 2003 and 4.4% in 2005 (12). Contrary to the 
experience in the United States and Europe (22), it 
is rather surprising to observe that this trend in the 
HIV epidemic (with an almost three-fold increase 
over the study period) in the country did not have 
any remarkably positive impact on the frequency 
of lymphoma in Ibadan during the study period. 
Suffice to mention at this point that the low fre-
quency of lymphoma among our patients may 
be directly attributable to the fact that only a very 
small percentage of the estimated 3.9 million Nige-
rians with HIV infection receive the much-needed 
antiretroviral therapy while the majority succumbs 
to opportunistic infections. These two reasons may, 
therefore, severely limit the life expectancy in HIV 
patients before a lymphoma can develop or be di-
agnosed. 
In this study while there was a preponderance of 
high-grade histological subtypes of NHL, their com-
parative proportion has drastically declined after 
an initial marginal increase from an average pro-
portion of about 71.7% of all NHL cases reported 
in the series by Okpala et al. (13) during 1974-1989, 
from 79.1% in 1991 to about 18.2% in 2005. This 
decline involved the three histological subtypes Oluwasola AO et al. Declining incidence of lymphomas in Nigeria
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of high-grade NHL, including BL. The prevalence 
of extranodal NHL has risen remarkably over the 
decades from a reported prevalence of 9.8% found 
by Thomas et al. during 1981-1998 (23) to 53.5% 
in the present study. However, this is still relatively 
low when compared with the prevalence rates of 
76% (24) and 87% (25) reported in the series of 
HIV patients. There were no cases of intracerebral 
or primary body cavity NHL. These findings further 
corroborate the lack of impact of the HIV epidemic 
on the pattern of occurrence of lymphoma in the 
country since these two types of NHL are AIDS de-
fining entities. The demographic patterns of vari-
ous histological grades of NHL did not significantly 
differ from the last local review (13).
In Europe and the United States, NHL is the com-
monest malignancy in paediatric AIDS patients, 
and approximately one-third of cases are BL (22).
There are three clinical subtypes of BL: endemic 
(eBL), sporadic (sBL), and AIDS-related BL (AIDS-
BL). Characteristically, eBL occurs almost exclusive-
ly in Africa, has a peak of incidence at seven years 
of age, a preponderance of males over females, and 
is associated with EBV in virtually 100% of cases. 
The predominant sites of involvement are the jaws 
and abdomen (26). AIDS-BL occurs with a peak at 
10-19 years of age and frequently involves lymph 
nodes and the bone marrow (27). In this study 
however, the modal age-group of occurrence of 
BL was in the first decade, jaw tumours were the 
commonest modes of presentation, and sites com-
monly associated with AIDS-BL, namely bone mar-
row and lymph nodes, were infrequently involved. 
There was no record of involvement of bone mar-
row while nodal manifestation represents 8.9% of 
all cases seen.  
HIV-associated HL presents in an aggressive fash-
ion, often with extranodal or bone marrow in-
volvement (28). A distinctive feature of HIV-asso-
ciated HL is the lower frequency of mediastinal 
lymphadenopathy compared to non-HIV-associa- 
ted HL (29). In addition, most cases are of either 
mixed cellularity or lymphocyte-depleted subtype 
and show expression of EBV-associated proteins in 
Reed-Sternberg cells. In this series, HL accounted 
for 12.5% of all lymphoma cases over the study pe-
riod. Extranodal involvement was infrequent hav-
ing occurred in only about 11.3% of the patients. 
The most frequently-encountered histological sub-
type is the nodular sclerosis type, which was diag-
nosed in 40% of the 80 cases seen. It was followed 
by the mixed cellularity subtype. There were no 
cases of bone marrow or mediastinal involvement. 
It is, however, not surprising that the only cases 
of intestinal, splenic and liver involvement were of 
the mixed cellularity and lymphocyte-depleted his-
tological subtypes. The latter two histological sub-
types only constitute about 32.6% of all the cases. 
The relatively-infrequent occurrence at the extran-
odal sites and the rarity of lymphocyte-depleted 
subtype in this series lend credence to the inference 
that the HIV epidemic in the country has not sig-
nificantly impacted on the pattern of occurrence of 
lymphoma seen here. 
The significance of the finding of a lack of signifi-
cant fingerprint of the HIV/AIDS epidemic on the 
epidemiology of lymphoma in this region of the 
country is that it corroborates earlier assertion that 
the degree of immune dysfunction at AIDS diag-
nosis, as measured by CD4 cell counts, was less in 
Africa than in industrial countries, and the median 
survival times are much shorter (30). As the risk of 
NHL in AIDS and other immunodeficiency states 
is related to the degree of immune dysregulation 
(31), it could be that the apparently low risk of HIV-
associated lymphoma in Nigeria, as in some other 
African countries, is the result of competing mor-
tality, particularly from infectious diseases in AIDS 
patients with relatively low levels of immunosup-
pression. 
The unavailability of immunohistochemistry, flow 
cytometry, and cytogenetics precluded the re-cate-
gorization of these malignancies according to the 
recent World Health Organization (WHO)’s clas-
sification of haemato-lymphoid malignancies by 
cytogenetic studies for further sub-classification of 
our cases.
Conclusions
While lymphomas still rank among the leading 
cancers in Ibadan, Nigeria, its incidence has, how-
ever, declined in recent decades. This decline was 
independently demonstrated in both NHL and HL. 
The HIV/AIDS epidemic being experienced in the 
country may not have influenced the pattern of oc-
currence of both major histomorphological types 
of lymphoma in Ibadan. However, our study was 
limited by our inability to use the WHO’s classifi-
cation of haemato-lymphoid malignancies and the 
non-availability of the HIV status of the patients. To 
this effect, a prospective study is being embarked on 
by this group involving serological analysis of HIV 
in lymphoma patients, and this hopes also to in-
corporate the WHO’s classification of malignant 
lymphomas as immunohistochemistry service has 
commenced in our centre.
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